Screener
Capricor Therapeutics CAPR Business Segments — Operating Income
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Capricor Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.
The source filing: Capricor Therapeutics’s 10-Q, filed May 13, 2026.
- Filed
- May 13, 2026, 5:20 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001104659-26-060382
| Total revenue | Three months ended March 31, 2026 / — | Three months ended March 31, 2025 / — |
|---|---|---|
| Stock-based compensation expense | 2,791,874 | 3,000,814 |
| Depreciation and amortization | 253,355 | 190,486 |
| Total general and administrative expense | 9,395,941 | 6,067,376 |
| Operating loss | (36,772,853) | (24,982,948) |
| Investment income | 2,904,506 | 729,542 |
| Other income (expense) | (72,998) | (138,188) |
| Total non-operating income, net | 2,831,508 | 591,354 |
| Loss before income taxes | (33,941,345) | (24,391,594) |
Item 1. Financial Statements.
FAQ
- What is Capricor Therapeutics's business segments — operating income?
- Capricor Therapeutics (CAPR) reported business segments — operating income of -$36.77M in Q1 2026.
- How has Capricor Therapeutics's business segments — operating income changed year-over-year?
- Capricor Therapeutics's business segments — operating income decreased by 47.2% year-over-year, from -$24.98M to -$36.77M.
- What does business segments — operating income mean?
- This metric represents the profit or loss generated from the company's core business operations before accounting for interest, taxes, and non-operating items. It reflects the efficiency of the company's primary research, development, and commercialization activities. For a biotechnology firm, this highlights the burn rate associated with advancing clinical pipelines.
Ask your AI about Capricor Therapeutics's business segments — operating income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude